Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.49 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MGAM | O43451 | 2/20 | 0.49 |
| ▸ | SI | P14410 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31708310 | 0.90 | GAA (0.47) | GAAACHENPC1MGAMSI | |
| SCHEMBL6843275 | 0.82 | KDM4E (0.57) | GAAACHENPC1MGAMSI | |
| SCHEMBL4740620 | 0.79 | GAA (0.48) | GAAACHENPC1MGAMSI | |
| Ayapin SCHEMBL6694210 | 0.75 | KDM4E (0.57) | GAAACHENPC1MGAMSI | |
| Ayapin SCHEMBL30171405 | 0.75 | KDM4E (0.57) | GAAACHENPC1MGAMSI | |
| Dihydroxanthyletin SCHEMBL4741095 | 0.74 | GAA (0.60) | GAAACHENPC1MGAMSI | |
| SCHEMBL9464144 | 0.74 | ACHE (0.56) | GAAACHENPC1MGAMSI | |
| SCHEMBL28994323 | 0.72 | ALDH1A1 (0.59) | GAAACHENPC1MGAMSI | |
| SCHEMBL9464004 | 0.71 | GAA (0.53) | GAAACHENPC1MGAMSI | |
| SCHEMBL23303231 | 0.71 | GAA (0.47) | GAAACHENPC1MGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0333606-B1 | Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases | YEDA RES & DEV (IL) | 1994-06-08 | — | — | EP | claimed |
| US-5114721-A | Lymphocytes activated by exposure to antigen and surface treated with photoactive psoralen crosslinking agent | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1992-05-19 | — | — | US | claimed |
| WO-1990008529-A2 | 7-ALKOXYCOUMARINS, DIHYDROPSORALENS, AND BENZODIPYRANONES AS PHOTO-ACTIVATED THERAPEUTIC AGENTS AND INHIBITORS OF EPIDERMAL GROWTH FACTOR | LEHIGH UNIVERSITY (US) | 1990-08-09 | — | — | WO | claimed |
| EP-0333606-A2 | Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-09-20 | — | — | EP | claimed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-113214282-B | AChE/BACE1/GSK3 beta three-target inhibitor, preparation method thereof and application thereof in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2022-03-22 | — | — | CN | disclosed |
| EP-1553911-B1 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | UNIV OHIO STATE RES FOUND (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20070154945-A1 | Immobilized biomolecule and method of detecting substance capable of interacting with biomolecule | NISSHINBO INDUSTRIES, INC. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-7150967-B2 | Fluorescent tags for amino acid and nucleic acid analysis | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 2006-12-19 | — | — | US | disclosed |
| US-20040018517-A1 | Fluorescent tags for amino acid and nucleic acid analysis | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-01-29 | — | — | US | disclosed |
| EP-1144417-B1 | 4'-SUBSTITUTED-4',5'-DIHYDROPSORALENS AND THERAPEUTICAL USES THEREOF | BUCKMAN LABOR INC (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1144417-A1 | 4'-SUBSTITUTED-4',5'-DIHYDROPSORALENS AND THERAPEUTICAL USES THEREOF | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-5473083-A | Skin disorders, cancer, Aids | LEHIGH UNIVERSITY (US) | 1995-12-05 | — | — | US | disclosed |
| US-5356929-A | Skin, blood and bone marrow disorders | LEHIGH UNIVERSITY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0333606-B1 | Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases | YEDA RES & DEV (IL) | 1994-06-08 | — | — | EP | disclosed |
| US-5216176-A | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor | LEHIGH UNIVERSITY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5114721-A | Lymphocytes activated by exposure to antigen and surface treated with photoactive psoralen crosslinking agent | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1992-05-19 | — | — | US | disclosed |
| WO-1990008529-A2 | 7-ALKOXYCOUMARINS, DIHYDROPSORALENS, AND BENZODIPYRANONES AS PHOTO-ACTIVATED THERAPEUTIC AGENTS AND INHIBITORS OF EPIDERMAL GROWTH FACTOR | LEHIGH UNIVERSITY (US) | 1990-08-09 | — | — | WO | disclosed |
| EP-0333606-A2 | Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-09-20 | — | — | EP | disclosed |
| US-4260630-A | PSORIASIS, 3-CARBOXY OR CYANO-SUBSTITUTED PSORALEN DERIVATIVE WITH UV RADIATION | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018517-A1 | Fluorescent tags for amino acid and nucleic acid analysis | DNTT, DIMT1, NUDT1 | GAA 2591/4885ACHE 4489/4885NPC1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.